Page 15 - Source Gt Biopharma Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Source gt biopharma inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Source Gt Biopharma Inc Today - Breaking & Trending Today

GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results

Share this article
Share this article
BEVERLY HILLS, Calif., March 17, 2021 /PRNewswire/ GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company s proprietary NK cell engager (TriKE™) protein biologic technology platform is pleased to announce updated interim Phase I/II clinical trial results for the Company s lead therapeutic candidate, GTB-3550, being evaluated for the treatment of high-risk myelodysplastic syndromes (MDS) and refractory/relapsed acute myeloid leukemia (AML).
Reduction in Bone Marrow Blast Levels Achieved
To date, 9 patients have been enrolled in the Phase I/II Expansion clinical trial. Patients enrolled early in the Study (patients 1-4) were treated with doses of GTB-3550 below the anticipated therapeutic dose (RP2D) and maximum tolerated dose (MTD) to address possible safety concerns. All patients treated at the lower doses exhibited no signs of toxic ....

United States , Julie Seidel , Anthony Cataldo , David Castaneda , Beverly Hills , Susan Roush , Stern Investor Relations Inc , National Cancer Institute , Source Gt Biopharma Inc , Exchange Commission , University Of Minnesota , Gt Biopharma Inc , Bone Marrow Blast Levels , Cytokine Release Syndrome , Maximum Tolerated Dose , Clin Cancer , Chief Executive Officer , High Risk Myelodysplastic Syndromes , Acute Myeloid Leukemia , Securities Act , Investor Relations , Gt Biopharma , ஒன்றுபட்டது மாநிலங்களில் , ஜூலி சீடல் , அந்தோணி காதலிடோ , டேவிட் கஷ்டனேடா ,

GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results

GT Biopharma Announces Updated Interim GTB-3550 Trike™ Clinical Trial Results
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Julie Seidel , Anthony Cataldo , David Castaneda , Beverly Hills , Susan Roush , Stern Investor Relations Inc , National Cancer Institute , Source Gt Biopharma Inc , Exchange Commission , University Of Minnesota , Gt Biopharma Inc , Bone Marrow Blast Levels , Cytokine Release Syndrome , Maximum Tolerated Dose , Clin Cancer , Chief Executive Officer , High Risk Myelodysplastic Syndromes , Acute Myeloid Leukemia , Securities Act , Investor Relations , ஒன்றுபட்டது மாநிலங்களில் , ஜூலி சீடல் , அந்தோணி காதலிடோ , டேவிட் கஷ்டனேடா , பெவர்லி மலைகள் ,

GT Biopharma Adds University of Wisconsin--Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment

Anthony J. Cataldo, GT Biopharma s Chairman and Chief Executive Officer, commented: It is exciting to announce the addition of a second clinical trial site for our Phase I/II program of our novel GTB-3550 TriKE™ program. With this progress, we are closer to bringing our disruptive and target-directed NK cell engager approach to patients in need. We are grateful to the valiant patients and their families, as we continue to progress this initial indication trial of our first-in-class NK cell protein biologic cancer therapy.
GTB-3550 TriKE™ is being evaluated in patients age 18 and older with CD33+ malignancies (primary induction failure or relapsed acute myeloid leukemia [AML] with failure of one reinduction attempt, or high-risk myelodysplastic syndromes [MDS] progressed on two lines of therapy). The primary endpoint is to identify the maximum tolerated dose and safety of GTB-3550 TriKE™ therapy. Correlative objectives include the number, phenotype, activation status an ....

United States , Julie Seidel , Erica Warlick , Susan Roush , Anthonyj Cataldo , Vara Ganesh Nadiminti , Jefferys Miller , David Castaneda , Beverly Hills , Prnewswire Gt Biopharma Inc , Stern Investor Relations Inc , Source Gt Biopharma Inc , Madison Carbone Cancer Center , Exchange Commission , University Of Wisconsin , American Society Of Hematology , University Of Minnesota , Gt Biopharma Inc , Um Masonic Cancer Center , Natural Killer , Palliative Care , Consulting Chief Medical Officer , Principal Investigator , Cancer Center , Chief Executive Officer , American Society ,

GT Biopharma to Present at The Virtual 33rd Annual Roth Conference

GT Biopharma, Inc. (NASDAQ: GTBP) a clinical stage biopharmaceutical company focused on the development and commercialization of disruptive, target-directed Natural Killer (NK) cell engager immunotherapy protein biologic platform technology, TriKE™, for the treatment of cancer and infectious diseases, today announced that management will present at the Virtual 33rd Annual Roth Conference on Wednesday, March 17th, 2021 at 12:00 p.m. ET (9:00am PT). ....

Source Gt Biopharma Inc , Clinical Stage , Bio Pharma , Forward Looking Statements , Biopharmaceutical Company , Natural Killer , மருத்துவ நிலை , உயிர் பார்மா , முன்னோக்கி பார்க்கிறது அறிக்கைகள் , இயற்கை கில்லர் ,

GT Biopharma to Present at The Virtual 33rd Annual Roth Conference

GT Biopharma to Present at The Virtual 33rd Annual Roth Conference
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Julie Seidel , David Castaneda , Beverly Hills , Susan Roush , Exchange Commission , Prnewswire Gt Biopharma Inc , Source Gt Biopharma Inc , Stern Investor Relations Inc , University Of Minnesota , Gt Biopharma Inc , Natural Killer , Annual Roth Conference , Securities Act , Investor Relations , ஜூலி சீடல் , டேவிட் கஷ்டனேடா , பெவர்லி மலைகள் , சூசன் ரஷ் , பரிமாற்றம் தரகு , கடுமையான முதலீட்டாளர் உறவுகள் இன்க் , பல்கலைக்கழகம் ஆஃப் மினசோட்டா , இயற்கை கில்லர் , ஆண்டு ரோத் மாநாடு , பத்திரங்கள் நாடகம் , முதலீட்டாளர் உறவுகள் ,